RecruitingLung Cancer, Nonsmall Cell
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
Sponsor: Abramson Cancer Center at Penn Medicine
You may qualify if…
- ✓ Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
- ✓ Prior exposure to at least 1 line of therapy
- ✓ Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
- ✓ ECOG PS 0-2
You may not qualify if…
- ✕ Presence of a driver mutation that is susceptible to targeted therapy
- ✕ No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
- ✕ Other active invasive malignancy requiring ongoing therapy
- ✕ Evidence of progressing or untreated brain metastases
- ✕ Evidence or history of leptomeningeal disease
- ✕ Uncontrolled tumor related pain
- ✕ History of an autoimmune disease or IPF
Where it's recruiting
Pennsylvania
Philadelphia
Source: ClinicalTrials.gov · NCT04691817 · last updated 2026-01-07